Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29335014 | 0.76 | NOS3 (0.39) | NOS3NOS1NOS2 | |
| SCHEMBL481420 | 0.74 | TSHR (0.38) | — | |
| SCHEMBL12469558 | 0.68 | PDE10A (0.47) | — | |
| SCHEMBL6405355 | 0.67 | MAPKAPK2 (0.41) | NOS3NOS1NOS2 | |
| SCHEMBL4146257 | 0.66 | — | — | |
| SCHEMBL481780 | 0.66 | KMT2A (0.41) | — | |
| SCHEMBL14307889 | 0.65 | ESR1 (0.37) | ESR1ESR2 | |
| SCHEMBL3868375 | 0.64 | TYRO3 (0.35) | — | |
| SCHEMBL4477571 | 0.64 | NOS2 (0.50) | NOS3NOS1NOS2 | |
| SCHEMBL4490554 | 0.64 | HTT (0.50) | NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4364798-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | Annapurna Bio Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-3860998-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | ANNAPURNA BIO INC (US) | 2023-12-27 | — | — | EP | disclosed |
| CN-113490668-A | Compounds and compositions for treating diseases associated with APJ receptor activity | 安娜普尔纳生物股份有限公司 | 2021-10-08 | — | — | CN | disclosed |
| US-7956056-B2 | Certain 1H-imidazo[4,5-B]pyrazin-2(3H)-ones and 1H-imidazo[4,5-B]pyrazin-2-ols, compositions thereof, and methods for their use | CYTOKINETICS, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-20110014212-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INCORPORATED | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014212-A1 | Certain Chemical Entities, Compositions and Methods | TNNI3, TNNT2, TNNC1 | ESR1 3740/4885ESR2 3060/4885NOS3 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.